Need immediate assistance? Call 1-518-730-0559 (Us-Canada Toll Free) or Contact Us

 

Global Opioid Induced Constipation Treatment Market Owes Growth to Impressive Performance by Leading Players

Blog Description

The worldwide market for opioid induced constipation treatment is poised to expand at a remarkable pace in the coming years owing to a high level of competition among existing players and an increasing number of drugs in various stages of clinical trials. According to a report available on Market Research Reports Search Engine (MRRSE), the value of the market is anticipated to rise from US$0.4 bn in 2014 to US$4.8 bn by 2023 at an astounding 31.20% CAGR therein. The report has been published by Transparency Market Research.

Browse Full Global Opioid Induced Constipation Treatment Market Report with TOC :http://www.mrrse.com/opioidinduced-constipation-treatment-market

Growth in Developing Economies to Pick Up Pace by 2023

The worldwide opioid induced constipation treatment market is geographically segmented into Asia Pacific, Europe, North America, Latin America, and Rest of the World (RoW). Here’s a look at how the developed and developing regions fare in the global opioid induced constipation treatment market:

  • North America dominates the opioid induced constipation treatment market and is anticipated to retain its lead through 2023.
  • Factors such as the rapid approval and launch of drugs for the treatment of opioid induced constipation, the increase in the number of people suffering from OIC, the presence of favorable government initiatives, and the availability of pipeline drugs have driven the North America opioid induced constipation treatment market.
  • The opioid induced constipation treatment markets in Latin America, Asia Pacific, and the Rest of the World have been witnessing rather gradual growth owing to the high cost of the therapy, a decreased level of awareness among the people, and lesser penetration of opioid to treat chronic pain.
  • The Latin America, Asia Pacific, and RoW markets for opioid induced constipation treatment are likely to gain momentum in the coming years thanks to the rise in patient-physician awareness and favorable amendments in the regulations of several countries.

Rise in Business Alliances Strengthening Growth of OIC Treatment Market

Even though the number of players in the OIC treatment is low, the demand for the therapy is rather high, which has resulted in intense competition among the vendors. Some of the top companies operating in the global opioid induced constipation treatment market are Cosmo Pharmaceuticals, C.B. Fleet Company, Inc., Daewoong Co. Ltd., Abbott Laboratories, Boehringer Ingelheim GmbH, Valeant Pharmaceuticals International, Inc., Bayer AG, AstraZeneca plc, and Takeda Pharmaceutical Company Limited.

Browse the full Press Release of Global Opioid Induced Constipation Treatment Market at http://www.mrrse.com/global-opioidinduced-constipation-treatment-market

There has been a surge in mergers and acquisitions among leading companies in the opioid induced constipation treatment market in order to commercialize OIC medicines. Listed below are two of the most promising developments to have taken place in this avenue.

  • In October 2014, Sucampo and Takeda entered into a global development and commercialization agreement for Amitiza, a prescription drug for the treatment of chronic idiopathic constipation.
  • In March 2015, Daiichi Sankyo and AstraZeneca signed a co-commercialization agreement for opioid-induced constipation drug Moventik in the US.

Developments such as these have had a positive impact on the global market for opioid induced constipation treatment.